Lv5
1410 积分 2022-08-16 加入
Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma
24天前
已关闭
Cancer cell therapies: global clinical trial trends and emerging directions
26天前
已完结
Cancer cell therapies: global clinical trial trends and emerging directions
26天前
已完结
Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study
1个月前
已完结
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
1个月前
已关闭
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
1个月前
已完结
Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor
4个月前
已完结
Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy
4个月前
已完结
Interleukin-1 receptor accessory protein (IL-1RAP): A magic bullet candidate for immunotherapy of human malignancies
4个月前
已完结
皖公网安备34019202002308
